Page 6 - Johnson & Johnson

J&J plans to test Covid-19 vaccine in ages 12-18, younger ages to follow

NEW YORK (Reuters) - Johnson & Johnson plans to start testing its experimental COVID-19 vaccine in youths aged 12 to 18 as soon as possible, and the company's previous experience with the same technology in a vaccine successfully used in children could give it a leg up with regulators.

Delhi High Court defers hearing in petitions against NAA to December 7

50 petitions pending in court, court asks each petitioner to submit its arguments within five pages

AstraZeneca resumes US Covid vaccine trial; J&J prepares for same next week

(Reuters) - AstraZeneca Plc has resumed the U.S. trial of its experimental COVID-19 vaccine after approval by regulators, and Johnson & Johnson is preparing to resume its trial on Monday or Tuesday, the companies said on Friday.

World Coronavirus Dispatch: China finds infection risk in frozen food packs

Brazil's weekly cases lowest in 5 months, New Zealand has first community case in three weeks, Israel eases curbs and other pandemic-related news across the globe

Race for coronavirus cure hits reality as clinic complications mount

Regulators and drugmakers have faced questions about whether political pressure was overwhelming scientific rigor ahead of the presidential election on Nov. 3

J&J to contribute up to $5 billion to potential US opioid settlement

(Reuters) - Johnson & Johnson said on Tuesday it will contribute up to $1 billion more to a potential settlement of lawsuits alleging it and other companies fueled the U.S. opioid epidemic, bringing its total payment to $5 billion.

Johnson & Johnson beats Q3 profit estimates, raises 2020 financial forecast

Johnson & Johnson boosted revenue slightly and doubled its third-quarter profit, mainly due to a $4 billion charge for litigation costs in the year-ago quarter. The health care giant blew past Wall Street expectations and raised its financial forecast for the year. Meanwhile, the New Brunswick, New Jersey-based company disclosed late Monday that it had to temporarily pause its huge, late-stage study of a potential COVID-19 vaccine due to an unexplained illness in a study participant. Such pauses are not unusual in big studies, and it's unknown whether the participant one of 60,000 planned for the global study got J&J's shot or a placebo. The world's biggest maker of health care products on Tuesday reported net income of $3.55 billion, or $1.33 per share, up 103% from $1.75 billion, or 66 cents per share, in 2019's third quarter. Excluding one-time gains and expenses, adjusted net income was $5.87 billion, or $2.20 per share, up from $5.67 billion, or or $2.12 per share, a ...

S&P 500, Dow slip on J&J vaccine worries; Apple, Amazon prop up Nasdaq

The Dow Jones Industrial Average fell 72.57 points, or 0.25 per cent, at the open

Top headlines: Wipro Q2 profit dips, GoAir pilots stop P&W engine mid-air

From Wipro reporting decline in Q2 profit year-on-year, Godrej Properties buying land in Bengaluru to J&J pausing Covid vaccine, Business Standard brings you top news of the evening

J&J confirms pausing Covid-19 vaccine trial because of unexplained illness

Earlier this month, Johnson & Johnson joined the short list of vaccine makers that have moved an experimental coronavirus shot into late-stage human studies

J&J Covid-19 vaccine produces strong immune response in early trials

A leading Covid-19 vaccine candidate developed by global healthcare company Johnson & Johnson produced a strong immune response against novel coronavirus in early-to-mid stage clinical trials, a report said.

World Coronavirus Dispatch: J&J announces final stage trials of vaccine

French biz confidence up despite resurgence, China eases entry rules for some foreigners, tough times for airlines as attempts to reopen falter, and other pandemic-related news across the globe

Johnson & Johnson kicks off giant study of single shot Covid-19 vaccine

J&J became the fourth vaccine maker to move its candidate into late-stage human studies in the US

Trump suggests Pfizer could win first US approval for Covid-19 vaccine

'Pfizer's doing really well', Trump said in an interview

Johnson & Johnson to buy Momenta Pharmaceuticals for $6.5 billion

The deal is the latest sign drug companies are looking for ways to bulk up even as the coronavirus pandemic upends other businesses

Britain lines up more potential Covid-19 vaccines with J&J, Novavax deals

Britain and the United States are in the lead with six vaccine deals with drugmakers each, as companies and governments worldwide work overtime to find a vaccine against the pandemic disease

Hyderabad-based Biological E joins hands with J&J for Covid-19 vaccine

The vaccine candidate is in phase 1/2a clinical trials

US inks $1.5 bn deal with Moderna for 100 mn doses of Covid-19 'vaccine'

The US government previously gave Moderna around $1 billion to fund its research efforts, bringing total US funding to around $2.5 billion

Johnson & Johnson's Covid-19 vaccine protected monkey in single shot

A leading candidate of Covid-19 vaccine developed by global healthcare company Johnson & Johnson raised neutralising antibodies and robustly protected monkeys against SARS-CoV-2, the virus that causes Covid-19.

Emergent signs 5-year deal to make drug used in J&J's Covid-19 vaccine

The news follows a $135 million deal struck by the two companies in April, to use Emergent's manufacturing facilities to speed up the development and production of its vaccine candidate